ckd-386
Small moleculeexperimental
Clinical trial activity
11 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Aug 31, 2018 (NCT03609606)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05698043 | Phase 1 | Jul 17, 2023 | Chong Kun Dang Pharmaceutical |
| NCT05552495 | Phase 1 | Sep 23, 2022 | Chong Kun Dang Pharmaceutical, Government of Korea |
| NCT05245084 | Phase 1 | Mar 15, 2022 | Chong Kun Dang Pharmaceutical |
| NCT04987970 | Phase 1 | Aug 11, 2021 | Chong Kun Dang Pharmaceutical |
| NCT04694989 | Phase 1 | Feb 20, 2021 | Chong Kun Dang Pharmaceutical, H Plus Yangji Hospital |
| NCT04673864 | Phase 1 | Jan 17, 2021 | Chong Kun Dang Pharmaceutical, H Plus Yangji Hospital |
| NCT04223895 | Phase 1 | Feb 1, 2020 | Chong Kun Dang Pharmaceutical, Yangji Hospital |
| NCT04388215 | Phase 3 | Oct 23, 2019 | Chong Kun Dang Pharmaceutical |
| NCT04312698 | Phase 3 | Aug 29, 2019 | Chong Kun Dang Pharmaceutical |
| NCT03920579 | Phase 1 | Apr 1, 2019 | Chong Kun Dang Pharmaceutical, Gachon University |
| NCT03609606 | Phase 1 | Aug 31, 2018 | Anam Hospital, Chong Kun Dang Pharmaceutical |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chong Kun Dang Pharmaceutical | For profit | 11 | 11 | 2 | 2018 |
| H Plus Yangji Hospital | Academic/Hospital | 2 | 0 | 1 | 2021 |
| Anam Hospital | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Gachon University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Government of Korea | Government | 1 | 0 | 1 | 2022 |
| Yangji Hospital | Academic/Hospital | 1 | 0 | 1 | 2020 |
6 organizations
Page 1 / 1